Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Desmopressin in Cardiac Surgery

This study has been completed.
Information provided by:
Università Vita-Salute San Raffaele Identifier:
First received: June 15, 2006
Last updated: October 20, 2015
Last verified: May 2013

Patients undergoing cardiac surgery could develop excessive perioperative bleeding requiring transfusions of blood products.

Desmopressin (DDAVP), already used for patients with von Willebrand syndrome, could reduce bleeding and transfusion requirements in these patients when administered ev (0.3 mg/kg) in 20-30 minutes postoperatively.

Condition Intervention Phase
Blood Loss, Surgical
Postoperative Hemorrhage
Drug: Desmopressin (DDAVP)
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Efficacy of Desmopressin (1-deamin0-8-D-arginine-vasopressin) in Reducing Active Microvascular Bleeding After Cardiac Surgery

Resource links provided by NLM:

Further study details as provided by Università Vita-Salute San Raffaele:

Primary Outcome Measures:
  • Reduce transfusions

Secondary Outcome Measures:
  • Reduced bleeding
  • Reduce time on mechanical ventilation
  • Reduced ICU and Hospital stay
  • Reduced mortality

Study Start Date: June 2006
Study Completion Date: September 2010
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Desmopressin (DDAVP) Drug: Desmopressin (DDAVP)
Placebo Comparator: Placebo Drug: Placebo


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • undergoing cardiac surgery
  • excessive bleeding

Exclusion Criteria:

  • age<18 y
  • not signing written consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00337766

Istituto Ospedaliero Fondazione Poliambulanza
Brescia, Italy
Istituto Policlinico S.Donato
Milano, Italy
Università Vita-Salute San Raffaele, Milano, Italia e Istituto Scientifico San Raffaele, Milano, Italia
Milan, Italy, 20132
Azienda Ospedaliera Universitaria Pisana
Pisa, Italy
Sponsors and Collaborators
Università Vita-Salute San Raffaele
Study Director: Giovanni Landoni, MD Università Vita-Salute San Raffaele, Milano, Italia e Istituto Scientifico San Raffaele, Milano, Italia.
Principal Investigator: Giuseppe Crescenzi, MD Università Vita-Salute San Raffaele, Milano, Italia e Istituto Scientifico San Raffaele, Milano, Italia.
  More Information

Publications: Identifier: NCT00337766     History of Changes
Other Study ID Numbers: DS/URC/ER/mm 151/DG
Study First Received: June 15, 2006
Last Updated: October 20, 2015

Keywords provided by Università Vita-Salute San Raffaele:
Blood Loss
Postoperative Blood loss

Additional relevant MeSH terms:
Postoperative Hemorrhage
Blood Loss, Surgical
Pathologic Processes
Postoperative Complications
Intraoperative Complications
Deamino Arginine Vasopressin
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs processed this record on April 28, 2017